Ocrevus Predicted to Be a Billion-dollar Blockbuster
September 4, 2018
From: Multiple Sclerosis News Today By: Ed Tobias The research firm Spherix Global Insights, which analyzes trends in the pharmaceutical
From: Multiple Sclerosis News Today By: Ed Tobias The research firm Spherix Global Insights, which analyzes trends in the pharmaceutical
The latest quarterly anemia report from Spherix Global Insights indicates a receptive audience for biosimilar erythropoietin stimulating agents (ESAs), but
According to Spherix Global Insights, data from over 1,000 psoriatic arthritis patients who recently switched therapies reveals that clinical factors,
Janssen’s Simponi Aria and BMS’ Orencia seem to be settling into their respective niches, but neither brand is anticipated to
According to a recent study conducted by Spherix Global Insights, US dermatologists (n=104) report significantly higher satisfaction with Dupixent than
According to Spherix Global Insights’ latest quarterly release of RealTime Dynamix™: Psoriasis, adoption of Tremfya as a psoriasis treatment is
According to a new report by Spherix Global Insights, Janssen’s Remicade is taking a dual hit from the expansion of
EU5 adoption of Pfizer’s Xeljanz and Eli Lilly’s Olumiant has been largely limited to rheumatologists practicing in Germany, according to
European neurologists predict substantial uptake of Roche’s Ocrevus among primary progressive multiple sclerosis patients driven by favorable market access status
At nearly two years post launch, close to 90% of nephrologists are using Veltassa compared to 61% of cardiologists and
From: Specialty Pharma Time By: Lauren Santye Although there are a growing number of rheumatologists in the United States who
Despite an increasing user base, Cosentyx share has remained unchanged over the past six months, according to recently released data
